Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
- Taiho’s HSP90 Inhibitor Extends PFS in GIST
February 24, 2021
- Lusefi’s OD Film Version Filed in Japan: Taisho
February 24, 2021
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Chugai to Develop Atea’s COVID-19 Drug AT-527 in Japan
February 22, 2021
- Japan-Bound Flights for COVID-19 Vaccines Get Underway: Pfizer, DHL, ANA
February 22, 2021
- Mitsubishi Tanabe, Keio University Tie Up for Research of Neutralizing Antibodies for COVID-19
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Kyowa Kirin’s Novel Antibody Hits Primary Goal in Global PII for Atopic Dermatitis
February 19, 2021
- Ono Files Opdivo for Adjuvant Therapy for Esophageal Cancer in Japan
February 19, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
- Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
- FoundationOne Approved as a CDx for Pemigatinib: Chugai
February 17, 2021
- Shionogi Pharma Set to Expand CDMO Biz with Continuous Manufacturing, Eyes 10 Billion Yen Sales in FY2024
February 17, 2021
- Stella Pharma Recalls Cancer Radiation Therapy over Flawed Testing at Kyowa CritiCare
February 17, 2021
- BMS Joins Hands with Tokyo Medical and Dental University on Fibrosis Research
February 17, 2021
- Japan’s 1st Humira Biosimilar Hits Market
February 16, 2021
- Number of Flu Patients Tanks to 1/1,000th in January vs Previous 5-Year Average: Survey
February 16, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…